S-fimbriae mediated adhesion ofEscherichia coli to human buccal epithelial cells is age independent

Summary S-fimbriatedEscherichia coli, which cause sepsis and meningitis in the newborn, bind to sialic acid-containing glycoprotein structures on the surface of human buccal epithelial cells. The dependence of this binding on host age was examined. S-fimbriatedE. coli adhered in comparable numbers to cells in newborns, infants, children and adults (23.0 ± 8.6; 23.1 ± 11.5; 24.7 ± 7.9; 28.9 ± 8.8). Thus, the increased susceptibility of neonates to infections caused by S-fimbriatedE. coli cannot be explained by enhanced adhesion to epithelial cells.

---

Die S-Fimbrien vermittelte Adhäsion von Escherichia coli an menschliche Mundschleimhautzellen ist altersunabhängig

Zusammenfassung S-Fimbrien tragendeEscherichia coli, die Sepsis und Meningitis im Neugeborenenalter verursachen, binden an sialinsäurehaltige Glycoproteine auf der Oberfläche menschlicher Mundschleimhautzellen. Wir untersuchten die Abhängigkeit der Bindung vom Alter des Schleimhautzellenspenders. S-Fimbrien tragendeE. coli banden in vergleichbarer Zahl an Zellen von Neugeborenen, Säuglingen, älteren Kindern und Erwachsenen (23,0 ± 8,6; 23,1 ± 11,5; 24,7 ± 7,9; 28,9 ± 8,8). Die vermehrte Empfänglichkeit von Neugeborenen für Infektionen, die durch S- Fimbrien tragendeE. coli verursacht werden, kann nicht mit einer verstärkten Adhäsion an Mundschleimhautzellen erklärt werden.

     

Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia

Proliferating cells, particularly the tumor cells, express a dimeric isoenzyme of pyruvate kinase, termed M2-PK. It's a direct target of several oncoproteins; the determination of fecal tumor pyruvate kinase type M2 (M2-PK) might be another promising tool for colorectal cancer (CRC) screening. In this study, we have evaluated fecal M2-PK as a screening biomarker for colorectal neoplasia. It was compared against fecal occult blood (FOB) and colonoscopy. Three hundred and seventeen consecutive subjects from 4 different centers were included. Stool specimens were collected before purgation, processed appropriately and were tested for FOB and quantitatively analyzed for M2-PK. Colonoscopies were performed by experienced endoscopists who were unaware of fecal assay results. At cutoff value of 4 U/ml, fecal M2-PK assay had a sensitivity, specificity, PPV and NPV of 81.1, 86.7, 71.1 and 61.9% respectively for diagnosing CRC whereas FOBT showed a sensitivity of 36.5%, specificity of 92.2%, PPV of 72.9% and NPV of 71.5% for CRC. Such low specificity of fecal M2-PK will lead to unacceptably high number of false positives if it is used for mass CRC screening, leading to unindicated colonoscopies with its associated inconveniences, risks and costs. CRC screening test must have high specificity; a high sensitivity is not as vital. To conclude, M2-PK was found to be a poor screening biomarker for CR neoplasia in a subject population at above average risk based on its prospective comparison with colonoscopy. These marginal performance characteristics do not permit its use as a screening tool for CR neoplasia in present clinical settings.     

Perinatal toxicity of endrin in rodents. II. Fetotoxic effects of prenatal exposure in rats and mice

The fetotoxic potential of endrin in the CD rat and CD-1 mouse was investigated. Endrin was administered as a solution in corn oil to groups of pregmant animals by gastric intubation at multiple dose levels throughout the period of organogenesis. The dams were sacrified prior to term and the fetuses were examined for skeletal and visceral anomalies. In addition, maternal livers and fetuses from rats in each dose level were analyzed for endrin content. In the mouse, endrin caused maternal liver enlargement at a dose of 0.5 mg/kg/day and reduced maternal weight gain at a dose of 1.0 mg/kg/day. Fetal weight and skeletal and visceral maturity were adversely affected at a dose of 1.0 mg/kg/day, but no teratogenic effect or embryo lethality was evident even at a dose level that produced maternal lethality (1.5 mg/kg/day). In the rat, endrin markedly reduced maternal weight at doses above 0.150 mg/kg/day but produced no apparent effects on the fetus. The data suggest that species differences in sensitivity to endrin may in part be due to differences in metabolism. Although endrin levels in rat fetuses at a maximally tolerated dosage level resembled those previously reported for the hamster, relatively less 12-ketoendrin was present, paralleling the change in fetal sensitivity.